These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3366131)

  • 1. Tumoral calcinosis revisited--common and uncommon features. Report of ten cases and review.
    Metzker A; Eisenstein B; Oren J; Samuel R
    Eur J Pediatr; 1988 Feb; 147(2):128-32. PubMed ID: 3366131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial tumoral calcinosis: a forty-year follow-up on one family.
    Carmichael KD; Bynum JA; Evans EB
    J Bone Joint Surg Am; 2009 Mar; 91(3):664-71. PubMed ID: 19255228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and genetic analysis of idiopathic normophosphatemic tumoral calcinosis in 19 patients.
    Zuo QY; Cao X; Liu BY; Yan D; Xin Z; Niu XH; Li C; Deng W; Dong ZY; Yang JK
    J Endocrinol Invest; 2020 Feb; 43(2):173-183. PubMed ID: 31535357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum calcitriol concentrations do not fall in response to hyperphosphatemia in familial tumoral calcinosis.
    Steinherz R; Chesney RW; Eisenstein B; Metzker A; DeLuca HF; Phelps M
    Am J Dis Child; 1985 Aug; 139(8):816-9. PubMed ID: 3839626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumoral calcinosis: new insights for the rheumatologist into a familial crystal deposition disease.
    Sprecher E
    Curr Rheumatol Rep; 2007 Jun; 9(3):237-42. PubMed ID: 17531178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity.
    Lyles KW; Burkes EJ; Ellis GJ; Lucas KJ; Dolan EA; Drezner MK
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1093-6. PubMed ID: 3998061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of familial tumoral calcinosis in a neonate and review of the literature.
    Polykandriotis EP; Beutel FK; Horch RE; Grünert J
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):563-7. PubMed ID: 15340747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperphosphatemic tumoral calcinosis: association with elevation of serum 1,25-dihydroxycholecalciferol concentrations.
    Prince MJ; Schaeffer PC; Goldsmith RS; Chausmer AB
    Ann Intern Med; 1982 May; 96(5):586-91. PubMed ID: 6896123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
    Chakhtoura M; Ramnitz MS; Khoury N; Nemer G; Shabb N; Abchee A; Berberi A; Hourani M; Collins M; Ichikawa S; El Hajj Fuleihan G
    Osteoporos Int; 2018 Sep; 29(9):1987-2009. PubMed ID: 29923062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial tumoral calcinosis.
    Alkhatib A; Burton LE; Carachi R
    Scott Med J; 2014 Nov; 59(4):e17-20. PubMed ID: 25351424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumoral calcinosis in an infant.
    Bostrom B
    Am J Dis Child; 1981 Mar; 135(3):246-7. PubMed ID: 7211781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
    Lammoglia JJ; Mericq V
    Horm Res; 2009; 71(3):178-84. PubMed ID: 19188744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumoral calcinosis and pseudoxanthoma elasticum.
    Najjar SS; Farah FS; Kurban AK; Melhem RE; Khatchadourian AK
    J Pediatr; 1968 Feb; 72(2):243-7. PubMed ID: 5635805
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive.
    Ichikawa S; Lyles KW; Econs MJ
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2420-3. PubMed ID: 15687324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis.
    Narchi H
    Pediatrics; 1997 May; 99(5):745-8. PubMed ID: 9113957
    [No Abstract]   [Full Text] [Related]  

  • 16. Proposal for a pathogenesis-based classification of tumoral calcinosis.
    Smack D; Norton SA; Fitzpatrick JE
    Int J Dermatol; 1996 Apr; 35(4):265-71. PubMed ID: 8786184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
    Frishberg Y; Topaz O; Bergman R; Behar D; Fisher D; Gordon D; Richard G; Sprecher E
    J Mol Med (Berl); 2005 Jan; 83(1):33-8. PubMed ID: 15599692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
    Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
    J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperphosphataemic tumoral calcinosis in Bedouin Arabs--clinical and radiological features.
    McGuinness FE
    Clin Radiol; 1995 Apr; 50(4):259-64. PubMed ID: 7729126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
    Garringer HJ; Fisher C; Larsson TE; Davis SI; Koller DL; Cullen MJ; Draman MS; Conlon N; Jain A; Fedarko NS; Dasgupta B; White KE
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4037-42. PubMed ID: 16868048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.